{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:14Z","timestamp":1793502914040,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00198-022-06648-9","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:02:58Z","timestamp":1672916578000},"page":"573-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study"],"prefix":"10.1007","volume":"34","author":[{"given":"Teerapat","family":"Tutaworn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeri W.","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaorui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin E.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae E.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-6940","authenticated-orcid":false,"given":"Joseph M.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"6648_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"6648_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/s2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6648_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732. https:\/\/doi.org\/10.1007\/s00198-017-3919-1","journal-title":"Osteoporos Int"},{"key":"6648_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 29:41\u201347. https:\/\/doi.org\/10.1007\/s00198-017-4242-6","journal-title":"Osteoporos Int"},{"key":"6648_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229. https:\/\/doi.org\/10.1016\/j.bone.2008.04.007","journal-title":"Bone"},{"key":"6648_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"6648_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925. https:\/\/doi.org\/10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"},{"key":"6648_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358. https:\/\/doi.org\/10.1210\/jc.2016-3170","journal-title":"J Clin Endocrinol Metab"},{"key":"6648_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296. https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"6648_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res 33:190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"key":"6648_CR11","doi-asserted-by":"publisher","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","volume":"144","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830. https:\/\/doi.org\/10.1016\/j.bone.2020.115830","journal-title":"Bone"},{"key":"6648_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje-21-0157","volume":"185","author":"G Grassi","year":"2021","unstructured":"Grassi G, Chiodini I, Palmieri S, Cairoli E, Arosio M, Eller-Vainicher C (2021) Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. Eur J Endocrinol 185:387\u2013396. https:\/\/doi.org\/10.1530\/eje-21-0157","journal-title":"Eur J Endocrinol"},{"key":"6648_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone 98:54\u201358. https:\/\/doi.org\/10.1016\/j.bone.2017.03.006","journal-title":"Bone"},{"key":"6648_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","volume":"31","author":"K Ebina","year":"2021","unstructured":"Ebina K, Hashimoto J, Kashii M et al (2021) Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol 31:485\u2013492. https:\/\/doi.org\/10.1080\/14397595.2020.1769895","journal-title":"Mod Rheumatol"},{"key":"6648_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"6648_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"6648_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int 103:50\u201354. https:\/\/doi.org\/10.1007\/s00223-018-0394-4","journal-title":"Calcif Tissue Int"},{"key":"6648_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381. https:\/\/doi.org\/10.1359\/jbmr.090716","journal-title":"J Bone Miner Res"},{"key":"6648_CR19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Miner Res"},{"key":"6648_CR20","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35:1207\u20131215. https:\/\/doi.org\/10.1002\/jbmr.3962","journal-title":"J Bone Miner Res"},{"key":"6648_CR21","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","volume":"28","author":"T Lehmann","year":"2017","unstructured":"Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28:3067\u20133068. https:\/\/doi.org\/10.1007\/s00198-017-4108-y","journal-title":"Osteoporos Int"},{"key":"6648_CR22","doi-asserted-by":"crossref","unstructured":"Japelj M, Vidmar G, Rajic AS, Pfeifer M, Kocjan T (2018) Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy. Endocrine Abstracts. Bioscientifica","DOI":"10.1530\/endoabs.56.P188"},{"key":"6648_CR23","unstructured":"Liebich G, Stoll D, Stoll D, Gonzalez-Rodriguez E, Gonzalez-Rodriguez E, Hans D, Lamy O, Aubry-Rozier B, Aubry-Rozier B (2019) Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The reolaus bone project. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Paris"},{"key":"6648_CR24","doi-asserted-by":"crossref","unstructured":"Aubry-Rozier B, Liebich G, Stoll D, Gonzalez-Rodriguez E, Hans D, Lamy O (2019) OP0085 Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The Reolaus Bone Project. BMJ Publishing Group Ltd","DOI":"10.1136\/annrheumdis-2019-eular.4175"},{"key":"6648_CR25","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","volume":"105","author":"D Kendler","year":"2020","unstructured":"Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105:e255-264. https:\/\/doi.org\/10.1210\/clinem\/dgz095","journal-title":"J Clin Endocrinol Metab"},{"key":"6648_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos Int"},{"key":"6648_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension Study. J Bone Miner Res 34:419\u2013428. https:\/\/doi.org\/10.1002\/jbmr.3622","journal-title":"J Bone Miner Res"},{"key":"6648_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/jbmr.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u2013151. https:\/\/doi.org\/10.1359\/jbmr.040920","journal-title":"J Bone Miner Res"},{"key":"6648_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00198-018-4460-6","volume":"29","author":"KE Naylor","year":"2018","unstructured":"Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R (2018) Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 29:1407\u20131417. https:\/\/doi.org\/10.1007\/s00198-018-4460-6","journal-title":"Osteoporos Int"},{"key":"6648_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","volume":"38","author":"H Kondo","year":"2020","unstructured":"Kondo H, Okimoto N, Yoshioka T et al (2020) Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. J Bone Miner Metab 38:894\u2013902. https:\/\/doi.org\/10.1007\/s00774-020-01126-w","journal-title":"J Bone Miner Metab"},{"key":"6648_CR31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ (2021) Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD Study Extension. J Bone Miner Res 36:921\u2013930. https:\/\/doi.org\/10.1002\/jbmr.4259","journal-title":"J Bone Miner Res"},{"key":"6648_CR32","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34:2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Miner Res"},{"key":"6648_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","volume":"103","author":"AM Horne","year":"2018","unstructured":"Horne AM, Mihov B, Reid IR (2018) Bone loss after romosozumab\/denosumab: effects of bisphosphonates. Calcif Tissue Int 103:55\u201361. https:\/\/doi.org\/10.1007\/s00223-018-0404-6","journal-title":"Calcif Tissue Int"},{"key":"6648_CR34","doi-asserted-by":"publisher","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478. https:\/\/doi.org\/10.1016\/j.bone.2020.115478","journal-title":"Bone"},{"key":"6648_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36:1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Miner Res"},{"key":"6648_CR36","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"6648_CR37","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162. https:\/\/doi.org\/10.1210\/clinem\/dgab321","journal-title":"J Clin Endocrinol Metab"},{"key":"6648_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","volume":"123","author":"A Fassio","year":"2019","unstructured":"Fassio A, Adami G, Benini C et al (2019) Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 123:191\u2013195. https:\/\/doi.org\/10.1016\/j.bone.2019.03.019","journal-title":"Bone"},{"key":"6648_CR39","unstructured":"The optimal sequential therapy after long term denosumab treatment. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05091099 Accessed May 13, 2022"},{"key":"6648_CR40","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","volume":"130","author":"L Triptoshkolnik","year":"2020","unstructured":"Triptoshkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I (2020) Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. Bone 130:115150. https:\/\/doi.org\/10.1016\/j.bone.2019.115150","journal-title":"Bone"},{"key":"6648_CR41","doi-asserted-by":"publisher","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https:\/\/doi.org\/10.3390\/jcm10010152","DOI":"10.3390\/jcm10010152"},{"key":"6648_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","volume":"54","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Terpos E (2016) Clinical vertebral fractures following denosumab discontinuation. Endocrine 54:271\u2013272. https:\/\/doi.org\/10.1007\/s12020-016-1030-6","journal-title":"Endocrine"},{"key":"6648_CR43","doi-asserted-by":"publisher","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","volume":"13","author":"M Laroche","year":"2020","unstructured":"Laroche M, Couture G, Ruyssen-Witrand A, Constantin A, Degbo\u00e9 Y (2020) Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep 13:100290. https:\/\/doi.org\/10.1016\/j.bonr.2020.100290","journal-title":"Bone Rep"},{"key":"6648_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I (2018) Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int 103:44\u201349. https:\/\/doi.org\/10.1007\/s00223-018-0389-1","journal-title":"Calcif Tissue Int"},{"key":"6648_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG (2019) Stopping denosumab. Curr Osteoporos Rep 17:8\u201315. https:\/\/doi.org\/10.1007\/s11914-019-00502-4","journal-title":"Curr Osteoporos Rep"},{"key":"6648_CR46","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36:1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Miner Res"},{"key":"6648_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-022-00962-4","author":"N Hong","year":"2022","unstructured":"Hong N, Shin S, Lee S, Kim KJ, Rhee Y (2022) Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-022-00962-4","journal-title":"Calcif Tissue Int"},{"key":"6648_CR48","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jbmr.4049","volume":"35","author":"EW Yu","year":"2020","unstructured":"Yu EW, Tsourdi E, Clarke BL, Bauer DC, Drake MT (2020) Osteoporosis management in the era of COVID-19. J Bone Miner Res 35:1009\u20131013. https:\/\/doi.org\/10.1002\/jbmr.4049","journal-title":"J Bone Miner Res"},{"key":"6648_CR49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00198-021-06274-x","volume":"33","author":"S Minisola","year":"2022","unstructured":"Minisola S, Cipriani C, Vigna E, Sonato C, Colangelo L, Monti F, Pepe J (2022) COVID pandemic and denosumab adherence. Osteoporos Int 33:943\u2013944. https:\/\/doi.org\/10.1007\/s00198-021-06274-x","journal-title":"Osteoporos Int"},{"key":"6648_CR50","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 80:920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"6648_CR51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12020-020-02333-1","volume":"69","author":"AD Anastasilakis","year":"2020","unstructured":"Anastasilakis AD, Evangelatos G, Makras P, Iliopoulos A (2020) Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. Endocrine 69:516\u2013518. https:\/\/doi.org\/10.1007\/s12020-020-02333-1","journal-title":"Endocrine"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06648-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:11:00Z","timestamp":1675876260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06648-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6648"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06648-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Institutional Review Board of Hospital for Special Surgery (HSS), New York (the study ID 2021\u20131960-AM1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publication"}},{"value":"ZW, JEL, and JEY have nothing to declare. TT has received a speaker honorarium from Amgen. JWN has received study medication from Eli Lilly and Radius. JML was paid as a consultant from ON Foundation, Kuros, Lenoss, Radius Health, Merck, Terumo BCT, and Mesentech. JML has received a research support from Merck, Novartis, and Radius Health. JML is a board member\/committee appointment of ON Foundation, UCB\/Amgen, and Lenoss.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}